Search results for "Infusions"

showing 10 items of 168 documents

Pharmacokinetics, pharmacodynamics, and safety of moss-aGalactosidase A in patients with Fabry disease.

2019

Moss-aGalactosidase A (moss-aGal) is a moss-derived version of human α-galactosidase developed for enzyme replacement therapy in patients with Fabry disease. It exhibits a homogenous N-glycosylation profile with >90% mannose-terminated glycans. In contrast to mammalian cell produced α-galactosidase, moss-aGal does not rely on mannose-6-phosphate receptor mediated endocytosis but targets the mannose receptor for tissue uptake. We conducted a phase 1 clinical trial with moss-aGal in six patients with confirmed diagnosis of Fabry disease during a 28-day schedule. All patients received a single dose of 0.2 mg/kg moss-aGal by i.v.-infusion. Primary endpoints of the trial were safety and pharmaco…

AdultMalePhases of clinical researchPharmacologyExcretion03 medical and health sciencesPharmacokineticsGermanyGeneticsmedicineHumansEnzyme Replacement TherapyInfusions IntravenousGenetics (clinical)030304 developmental biology0303 health sciencesKidneySphingolipidsbusiness.industry030305 genetics & heredityEnzyme replacement therapyMiddle Agedmedicine.diseaseFabry diseasemedicine.anatomical_structureTreatment OutcomePharmacodynamicsalpha-GalactosidaseFabry DiseaseFemaleGlycolipidsbusinessMannose receptorJournal of inherited metabolic disease
researchProduct

Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation …

2015

Purpose The MOSAIC (Multicenter International Study of Oxaliplatin/Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer) study has demonstrated 3-year disease-free survival (DFS) and 6-year overall survival (OS) benefit of adjuvant oxaliplatin in stage II to III resected colon cancer. This update presents 10-year OS and OS and DFS by mismatch repair (MMR) status and BRAF mutation. Methods Survival actualization after 10-year follow-up was performed in 2,246 patients with resected stage II to III colon cancer. We assessed MMR status and BRAF mutation in 1,008 formalin-fixed paraffin-embedded specimens. Results After a median follow-up of 9.5 years, 10-year OS rates in the bolus/…

AdultMaleProto-Oncogene Proteins B-rafOncologyCancer Researchmedicine.medical_specialtyOrganoplatinum CompoundsColorectal cancermedicine.medical_treatmentPopulationLeucovorinGlutamic AcidKaplan-Meier EstimateDNA Mismatch RepairDisease-Free SurvivalInternal medicineAntineoplastic Combined Chemotherapy ProtocolsOdds RatiomedicineHumansStage (cooking)Infusions IntravenouseducationAgedNeoplasm Stagingeducation.field_of_studyChemotherapybusiness.industryHazard ratioValineMiddle AgedPrognosismedicine.diseasedigestive system diseasesSurgeryOxaliplatinTreatment OutcomeOncologyChemotherapy AdjuvantFluorouracilColonic NeoplasmsInjections IntravenousMutationFemaleFluorouracilbusinessAdjuvantFollow-Up Studiesmedicine.drugJournal of Clinical Oncology
researchProduct

Buprenorphine or procaine for pain relief in acute pancreatitis. A prospective randomized study.

2001

To assess the analgesic efficacy and side effects of buprenorphine and procaine in patients with acute pancreatitis.Forty patients (average age, 50 years; 23 male) with acute pancreatitis or an acute bout of a chronic pancreatitis were prospectively randomized to receive buprenorphine or procaine for pain relief. Both analgesics were administered as constant intravenous (i.v.) infusions and additional analgesics were given on demand. Pain scores were assessed on a visual analogue scale. Close clinical control and laboratory checks were performed during the three-day study period.Patients receiving buprenorphine were significantly less likely to demand additional analgesics (1 versus 14 pati…

AdultMaleRandomizationAnalgesicPainlaw.inventionProcaineRandomized controlled triallawmedicineHumansProspective StudiesProspective cohort studyInfusions IntravenousAgedPain MeasurementAnalgesicsbusiness.industryGastroenterologyMiddle Agedmedicine.diseaseBuprenorphineAnalgesics OpioidPancreatitisAnesthesiaAcute DiseaseAcute pancreatitisPancreatitisFemalebusinessProcainemedicine.drugBuprenorphineScandinavian journal of gastroenterology
researchProduct

Efficacy and Tolerability of Biweekly Bevacizumab, Irinotecan, Folinic Acid and Fluorouracil Intravenous Bolus (BIFF Regimen) in Patients With Metast…

2011

Abstract Background We have extensively assessed a biweekly regimen of irinotecan plus folinic acid and fluorouracil bolus (IRIFAFU) in metastatic colorectal cancer (MCRC). Here, we report on the safety and activity of BIFF (bevacizumab plus IRIFAFU) regimen in 94 mCRC patients. Patients and Methods Bevacizumab 5 mg/kg (1 hour), and irinotecan 180 mg/m 2 (1hour) were given intravenously on day 1, 6S-folinic acid 250 mg/m 2 (2 hours), and fluorouracil 850 mg/m 2 (bolus) were given intravenously on day 2 every 2 weeks for a median of 9 cycles per patient (range, 1-12), and maintenance bevacizumab alone was delivered in 16 cases. Results Grade ≥ 3 hematologic toxicities were neutropenia (50%) …

AdultMaleRiskOncologyAntimetabolites Antineoplasticmedicine.medical_specialtyBevacizumabLeucovorinAngiogenesis InhibitorsAntibodies Monoclonal HumanizedIrinotecanFolinic acidBolus (medicine)Internal medicineBiomarkers TumorConfidence IntervalsmedicineHumansInfusions IntravenousAgedbusiness.industryGastroenterologyAntibodies MonoclonalMiddle AgedMETASTATIC COLORECTAL CANCER BEVACIZUMABmedicine.diseaseAntineoplastic Agents PhytogenicSurvival AnalysisBevacizumabIrinotecanRegimenItalyOncologyTolerabilityFluorouracilVitamin B ComplexDisease ProgressionCamptothecinFemaleFluorouracilColorectal NeoplasmsbusinessFebrile neutropeniamedicine.drugClinical Colorectal Cancer
researchProduct

Beta-adrenergic stimulation enhances left ventricular diastolic performance in normal subjects.

1997

To determine the effects of beta-adrenergic stimulation on transmitral Doppler echocardiography flow characteristics of left ventricular diastolic filling, we studied 10 healthy volunteers aged 23-31 years (mean age, 26.6 years) during intravenous infusion of isoprenaline in consecutive steps of 0.1, 0.2, 0.4, 0.75, and 1.5 micrograms/min (each for 15 min). Saline control infusion was given in the same manner in a crossover and blinded protocol. Compared with the infusion of placebo, stepwise increasing doses of isoprenaline caused a dose-related increase in early and late diastolic filling velocities and velocity-time integrals, a lengthening of the acceleration time, and a shortening of t…

AdultMaleStress testingDiastoleHemodynamicsBlood PressureDoppler echocardiographyVentricular Function LeftDouble-Blind MethodHeart RateIsoprenalineHeart ratemedicineHumansInfusions IntravenousPharmacologyAnalysis of VarianceCross-Over Studiesmedicine.diagnostic_testDose-Response Relationship Drugbusiness.industryIsoproterenolAdrenergic beta-AgonistsEchocardiography DopplerBlood pressureAnesthesiaCirculatory systemCardiology and Cardiovascular Medicinebusinessmedicine.drugJournal of cardiovascular pharmacology
researchProduct

Effect of intraarterial papaverine or nimodipine on vessel diameter in patients with cerebral vasospasm after subarachnoid hemorrhage.

2012

Papaverine (P) and nimodipine (N) are the most widely used vasodilators when angiographic and symptomatic vasospasm is present after subarachnoid aneurysmatic hemorrhage (SAH). Their effect is only short-lived and no direct comparisons have been undertaken to evaluate the action of both substances directly. We retrospectively assessed the effect of either P or N on angiographic diameter reduction and capillary blood flow.Fifteen SAH patients with secured aneurysms and cerebral vasospasm received intraarterial P, fifteen similar patients received N. As the primary endpoint, pre- and post-infusion arterial diameters and capillary blood flow were rated retrospectively on angiographies and comp…

AdultMaleSubarachnoid hemorrhageVasodilator AgentsIschemiaBrain IschemiaCerebral vasospasmModified Rankin ScalePapaverinemedicineHumansInfusions Intra-ArterialVasospasm Intracranialcardiovascular diseasesNimodipineAgedRetrospective StudiesAged 80 and overPapaverineAnalysis of Variancebusiness.industryVasospasmGeneral MedicineBlood flowCerebral ArteriesMiddle AgedSubarachnoid Hemorrhagemedicine.diseasenervous system diseasesCapillariesVasodilationAnesthesiaCerebrovascular CirculationSurgeryFemaleNimodipineNeurology (clinical)businessCarotid Artery Internalmedicine.drugBritish journal of neurosurgery
researchProduct

Continuous intravenous infusion of dipyridamole as adjunctive therapy in the treatment of thrombotic thrombocytopenic purpura.

2003

Abstract Thrombotic thrombocytopenic purpura (TTP) is an uncommon hematologic thrombotic disorder characterized by fever, hemorrhagic and neurologic signs. The advent of plasma exchange has dramatically improved the prognosis of this disease, which was once inevitably fatal. However, mortality rates remain significant. Antiplatelet drugs have been widely used in combination with plasma exchange. In this pilot study we investigated the effects of an adjunctive therapy consisting of the continuous, intravenous infusion of dipyridamole, a modality of administration that has not been previously tested in this setting. Sixteen untreated TTP patients, diagnosed consecutively at our clinic, receiv…

AdultMaleTime FactorsCombination therapyThrombotic thrombocytopenic purpuraPilot ProjectsMethylprednisolonelaw.inventionRandomized controlled trialRefractorylawRecurrencemedicineHumansPlateletIn patientProspective StudiesInfusions IntravenousPlasma ExchangePurpura Thrombotic Thrombocytopenicbusiness.industryPlatelet CountMortality rateRemission InductionHematologyDipyridamoleMiddle Agedmedicine.diseaseCombined Modality TherapyDipyridamoleTreatment OutcomeAnesthesiaFemalebusinessPlatelet Aggregation Inhibitorsmedicine.drugTransfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
researchProduct

Alteration of vancomycin pharmacokinetics during cardiopulmonary bypass in patients undergoing cardiac surgery.

2003

The alteration of vancomycin pharmacokinetics during cardiopulmonary bypass (CPB) in patients undergoing cardiac surgery was studied. Eighteen patients were enrolled in the study. Vancomycin (1 g) was intravenously infused one to two hours before surgery. Blood samples were taken before, during, and after CPB. Serum drug concentrations were determined by an automated fluorescence polarization immunoassay and adjusted, with a bayesian analysis, to a bi-compartmental model implemented in a pharmacokinetic system program. Serum creatinine, hematocrit, and plasma proteins were also measured before, during, and after CPB. During CPB, serum creatinine, hematocrit, and plasma protein values all de…

AdultMaleTime FactorsHematocritlaw.inventionchemistry.chemical_compoundPharmacokineticslawVancomycinBlood plasmaCardiopulmonary bypassMedicineHumansInfusions IntravenousAgedMonitoring PhysiologicPharmacologyVolume of distributionCreatinineCardiopulmonary Bypassmedicine.diagnostic_testbusiness.industryHealth PolicyAntibiotic ProphylaxisMiddle AgedBlood proteinsAnti-Bacterial Agentssurgical procedures operativechemistryAnesthesiaVancomycinFemalebusinesscirculatory and respiratory physiologymedicine.drugHalf-LifeAmerican journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
researchProduct

Precision and Bias of Target-Controlled Prolonged Propofol Infusion for General Anesthesia and Sedation in Neurosurgical Patients

2018

The aim of this study was to determine the relationship, precision, and bias of a propofol target-controlled infusion (TCI) system during prolonged infusion in neurosurgical patients. We retrospectively included patients undergoing general anesthesia for elective neurosurgical removal of brain tumors and postoperative sedation in the intensive care unit over a period of 3 months. TCI of propofol (Diprifusor - Marsh model) and remifentanil were used for general anesthesia and sedation. We compared propofol blood concentration (Cmeas) measured by liquid chromatography-mass spectroscopy with predicted concentrations (Cpred) by the TCI system at 40 minutes (T0), 2 hours (T1), and 4 hours (T2) a…

AdultMaleTime FactorsSedationAnesthetic techniqueRemifentanilPharmacokineticAnesthesia GeneralMass SpectrometryNeurosurgical ProceduresTarget controlled infusionlaw.invention03 medical and health sciencesYoung Adult0302 clinical medicine030202 anesthesiologylawmedicineHumansPharmacology (medical)Computer-assisted continuous infusionPropofol TCILead (electronics)Infusions IntravenousPropofolAgedRetrospective StudiesPharmacologybusiness.industryBrain NeoplasmsPropofol infusionDrug administration030208 emergency & critical care medicineDrug infusionMiddle AgedIntensive care unitTolerabilityAnesthesiaLinear ModelsFemalemedicine.symptomPropofolbusinessAnesthetics Intravenousmedicine.drugChromatography LiquidTCI anesthesia
researchProduct

Replacement therapy for alpha-1-protease inhibitor deficiency in PiZ subjects with chronic obstructive lung disease

1988

In a six-month multicenter feasibility and safety study, 20 patients, who all had a congenital deficiency of alpha-1-protease inhibitor (A1PI) of the PiZ phenotype accompanied by a chronic obstructive lung disease, were treated with human-plasma-derived A1PI. A weekly dose of 60 mg/kg, administered intravenously, was shown to be sufficient to maintain patient serum levels above the threshold limit of 35 percent, the serum level of healthy persons of the MZ phenotype. This is supposed to be the minimal effective level for protection against the elastolytic attack of the lung and, therefore, satisfies one of the most important criteria of feasibility of long-term replacement therapy. The glob…

AdultMalealpha 1-Antitrypsin DeficiencymedicineHumansLung Diseases ObstructiveInfusions IntravenousAgedRadial immunodiffusionClinical Trials as TopicLungPancreatic Elastasebiologybusiness.industryBlood ProteinsGeneral MedicineMiddle AgedOuchterlony double immunodiffusionTrypsinmedicine.diseaseAlpha-1 Protease Inhibitor DeficiencyObstructive lung diseasePhenotypemedicine.anatomical_structureImmunologybiology.proteinFemaleAntibodyLung Volume MeasurementsbusinessNephelometrymedicine.drugThe American Journal of Medicine
researchProduct